The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates

The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates

Source: 
Yahoo/Benzinga
snippet: 

Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week. The sector started the week on a strong note, thanks to positive vaccine data reported by Moderna Inc (NASDAQ: MRNA).

The momentum faltered through the week after the broader market came under pressure amid fresh COVID-19 restrictions.